The Lp(a) Revolution: How 2026 Became the Year Cardiology Finally Learned to Treat Its Oldest Blind Spot

For more than sixty years, cardiologists have known about a form of cholesterol that behaves nothing like the kind measured on a standard lipid panel. It runs in families. It does not respond to statins. It does not care how thin you are, how many miles you run, or whether your LDL is pristine. It raises the lifetime risk of heart attack, stroke, and aortic stenosis by up to four fold, and roughly one in five people on Earth carry elevated levels of it. Its name is lipoprotein(a), pronounced “lipoprotein little a,” and until very recently, the only responsible thing a doctor could tell a patient with high levels was that we know it is a problem and we cannot do anything about it.

Presented By Our Partners

2026 is the year that sentence stops being true.

A generation of novel RNA therapeutics is now cycling through Phase 3 trials, along with the first oral Lp(a) lowering drug ever tested in humans. Results from several of these studies will read out over the next twelve to eighteen months, and cardiologists are preparing for what may be the largest shift in primary prevention since the statin era began. For a field that has spent four decades asking the same question in different ways, namely how to drop LDL low enough to stop heart attacks, the emergence of a second equally powerful lever represents something rarer than incremental progress. It represents a new category of preventive medicine.

The Cholesterol That Is Really a Genetic Bomb

Lipoprotein(a) was first described in 1963 by the Norwegian geneticist Kare Berg. In structure, it resembles LDL cholesterol with a twist. An additional protein called apolipoprotein(a), or apo(a), is covalently bonded to the LDL particle’s apoB component. That extra protein has two unusual properties. First, its concentration in the blood is almost entirely inherited, set by variations in the LPA gene on chromosome 6. Second, apo(a) looks remarkably similar to plasminogen, the body’s primary clot dissolving enzyme.

The combination is pathogenic in ways that standard LDL is not. Lp(a) drives atherosclerosis because it deposits cholesterol in artery walls just like any other LDL-like particle. It drives thrombosis because its plasminogen mimicry interferes with the body’s natural fibrinolytic machinery. And it drives aortic valve calcification through oxidized phospholipids that are preferentially carried on the apo(a) protein itself. One particle, three separate mechanisms, all converging on cardiovascular death.

Large mendelian randomization analyses, most prominently the work of Brian Ference at the University of Cambridge, demonstrated that Lp(a) is not merely correlated with disease but causally related. People who inherit genetic variants that lower Lp(a) enjoy lifelong cardiovascular protection that scales with the magnitude of the reduction. Conversely, people who inherit elevated Lp(a) levels carry that risk from birth. A 2022 analysis in the Journal of the American College of Cardiology, led by Sotirios Tsimikas at UC San Diego, estimated that roughly 1.4 billion people worldwide have Lp(a) levels above the 50 mg/dL threshold associated with significantly elevated cardiovascular risk. In the United States alone, that is about 63 million adults, the vast majority of whom have never been tested.

Why the First Generation of Therapies Failed

The story of why we have no existing Lp(a) drug is partly a story of biology and partly one of bad luck. Statins, the cornerstone of lipid lowering therapy, either do nothing to Lp(a) or actually raise it modestly. PCSK9 inhibitors such as evolocumab and alirocumab reduce Lp(a) by roughly 20 to 30 percent, which turns out to be insufficient to produce independent cardiovascular benefit in people with very high baseline levels. Niacin lowers Lp(a) but failed to improve outcomes in the AIM-HIGH and HPS2-THRIVE trials. Lipoprotein apheresis, the most aggressive existing option, filters Lp(a) out of the blood mechanically, but it requires weekly infusions, specialized centers, and regulatory authorization that is rarely granted outside Germany and a few other European markets.

For the roughly 20 percent of patients whose elevated cardiovascular risk comes predominantly from Lp(a) rather than LDL, none of these tools have been enough. The breakthrough did not come from a new pill in the traditional sense. It came from the realization that Lp(a) is perfectly suited for a genetic intervention. It is produced almost exclusively by the liver. It is controlled by a single gene. And its pathogenic effects can be largely eliminated if its circulating concentration can be driven low enough. The remaining question was how to shut down apo(a) production without shutting down the rest of the body’s lipid metabolism.

The Rise of RNA Therapeutics Targeted at the Liver

The answer came from two related technologies that matured in parallel over the past decade: antisense oligonucleotides and small interfering RNA. Both work by recognizing and degrading specific messenger RNA sequences inside liver cells, preventing a target protein from being produced. In the case of Lp(a), the target is the mRNA encoding apo(a). By silencing that single transcript, these drugs can reduce Lp(a) levels by 80 to 98 percent without altering LDL, HDL, triglycerides, or any other measured cholesterol component.

The antisense approach is represented by pelacarsen, developed by Ionis Pharmaceuticals and licensed to Novartis. Pelacarsen is a GalNAc conjugated oligonucleotide that delivers itself directly to hepatocytes via the asialoglycoprotein receptor. In earlier Phase 2 data published in the New England Journal of Medicine in 2020, pelacarsen reduced Lp(a) by 80 percent at the highest dose. Its Phase 3 trial, HORIZON, has enrolled over 8,300 patients with existing cardiovascular disease and elevated Lp(a), randomizing them to monthly subcutaneous pelacarsen injections or placebo with follow up for major cardiovascular events. Principal investigators include Steven Nissen at the Cleveland Clinic and Sotirios Tsimikas at UC San Diego. The primary readout is expected in late 2026, and cardiologists widely view it as the definitive test of the Lp(a) causal hypothesis.

The siRNA approach is led by olpasiran, developed by Arrowhead Pharmaceuticals and licensed to Amgen. Olpasiran uses the body’s own RNA interference machinery to cleave apo(a) mRNA, producing reductions of 95 to 98 percent at higher doses with dosing as infrequent as once every twelve weeks. Its Phase 2 OCEAN(a) DOSE study, published in NEJM in 2022, established both the magnitude and durability of the effect. The Phase 3 OCEAN(a) Outcomes trial, led by Michelle O’Donoghue and Marc Sabatine at Brigham and Women’s Hospital, is currently enrolling with results expected in 2027.

A third RNA entrant, lepodisiran from Eli Lilly, is another siRNA with similar properties and potentially even longer dosing intervals. Its Phase 3 ACCLAIM-Lp(a) trial is enrolling approximately 12,500 patients across more than 50 countries. Early data published in JAMA in 2024 showed a single dose produced Lp(a) reductions exceeding 94 percent persisting for over six months.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

The First Oral Drug: Muvalaplin

While the injectable RNA therapeutics have captured most of the attention, a quieter development may prove equally transformative in practice. Muvalaplin, an oral small molecule from Eli Lilly, works through a completely different mechanism. It disrupts the physical interaction between apo(a) and apoB that is required for Lp(a) particles to form in the first place. By preventing assembly rather than degrading the mRNA, muvalaplin produces measured Lp(a) reductions of approximately 85 percent in Phase 2 trials, with the convenience of once daily dosing.

The Phase 2 KRAKEN trial, led by Stephen Nicholls at Monash University and published in JAMA in 2024, randomized 233 adults with elevated Lp(a) to three dose levels of muvalaplin or placebo. The results were striking not only for the magnitude of Lp(a) reduction but for the safety profile. No significant elevation in liver enzymes. No signal for thrombosis. No off target effects on plasminogen activity. For a field that has worried that disrupting Lp(a) could theoretically interfere with the body’s ability to dissolve clots, KRAKEN’s safety data were deeply reassuring.

A Phase 3 cardiovascular outcomes trial of muvalaplin has been signaled by Lilly but not yet launched. If and when approval follows, muvalaplin would represent the first orally available Lp(a) lowering therapy in human history. That matters enormously for real world adoption, since the practical gap between a once daily pill and a subcutaneous injection given quarterly or monthly is wide enough to shape which patients ultimately receive treatment.

A Screening Problem as Big as the Treatment Problem

The emergence of effective therapy transforms an academic debate about Lp(a) screening into an urgent clinical question. Current U.S. guidelines from the American Heart Association and the National Lipid Association recommend one time Lp(a) measurement in all adults, and especially in those with a personal or family history of premature cardiovascular disease. European guidelines from the European Atherosclerosis Society go further and recommend universal one time screening. Yet in actual U.S. clinical practice, fewer than 10 percent of adults have ever had their Lp(a) measured. The reason has been straightforward. With no treatment available, many clinicians concluded the information was not actionable.

That calculus is changing rapidly. Samia Mora at Brigham and Women’s Hospital, one of the leading researchers on Lp(a) epidemiology, has argued in Circulation that universal one time screening should now be standard of care. Her case rests on three facts. Lp(a) levels are roughly stable across the lifespan, so there is no need for serial testing. Testing itself costs under 40 dollars and can be ordered reflexively alongside a routine lipid panel. And the patient population at highest risk is otherwise invisible to traditional cardiovascular risk calculators like the ASCVD Pooled Cohort Equations or the new PREVENT model from the AHA. Several U.S. health systems, including Cleveland Clinic and Intermountain Healthcare, have already moved toward reflex Lp(a) testing during routine lipid panels in all adults over 18.

Ethnic Disparities and the Global Burden

Lp(a) distribution is not random across populations. People of African descent have median levels roughly three times higher than those of European descent, and South Asian populations also carry elevated average levels. The reasons are genetic, driven by differences in LPA gene copy number and the number of “kringle IV type 2” repeats within the apo(a) protein. These differences help explain part of the unexplained cardiovascular risk gap between ethnic groups that traditional risk factors like LDL, blood pressure, and smoking have never fully accounted for.

The implication is that Lp(a) directed therapy may disproportionately benefit populations who have been chronically underserved by existing cardiovascular prevention. The challenge is that these same populations have historically been underrepresented in clinical trials. To their credit, HORIZON, OCEAN(a) Outcomes, and ACCLAIM-Lp(a) have all committed to enrollment targets that reflect the global burden of elevated Lp(a), including significant representation from African, Latin American, and South Asian populations. Whether those targets are actually met will shape the generalizability of the final results and the speed with which guideline committees adopt new recommendations.

The Question of Secondary Versus Primary Prevention

All three of the Phase 3 RNA trials enroll patients with established cardiovascular disease, a population in whom the benefit of lowering a known causal risk factor is easiest to detect in a reasonable trial duration. The harder question is whether Lp(a) directed therapy will eventually be used for primary prevention in people who have high Lp(a) but no existing disease. Given that Lp(a) exerts its pathogenic effect over decades, a truly conclusive primary prevention trial would need to run for fifteen to twenty years and enroll tens of thousands of participants. No sponsor is planning such a study.

In the absence of such a trial, regulators and guideline committees will likely follow the statin precedent. Once Lp(a) therapies prove cardiovascular benefit in secondary prevention, expanded use in high risk primary prevention populations will probably be permitted based on genetic evidence, surrogate outcomes, and clinical judgment. That pattern played out over roughly a decade for statins and more recently for PCSK9 inhibitors, and there is little reason to expect a different trajectory for Lp(a) therapy.

What This Means for Aortic Stenosis

One of the most underappreciated aspects of the Lp(a) story is its role in calcific aortic valve disease, the most common valvular condition in adults over 65 and the leading indication for surgical or transcatheter valve replacement. Lp(a) is one of the few modifiable risk factors causally linked to aortic stenosis progression, a conclusion reached through mendelian randomization studies by George Thanassoulis and colleagues at McGill University.

No currently approved therapy slows aortic valve calcification. If Lp(a) lowering therapies prove effective at delaying or preventing aortic stenosis in people with high Lp(a), the implications for the aging population are enormous. A recent analysis in JACC projected that even a 50 percent reduction in Lp(a) driven aortic stenosis cases could reduce annual U.S. valve replacement procedures by 15,000 to 20,000 within fifteen years of widespread therapy adoption. That would translate into billions of dollars of avoided procedures and, more importantly, years of added quality of life for patients who otherwise face open heart surgery or transfemoral valve replacement in their seventies and eighties.

Timeline and What to Watch

The most important near term milestones are the HORIZON trial readout for pelacarsen, expected in late 2026, and the OCEAN(a) Outcomes readout for olpasiran, expected in 2027. If HORIZON shows significant reduction in major cardiovascular events, FDA approval of pelacarsen for patients with established cardiovascular disease and elevated Lp(a) would likely follow in 2027. Olpasiran and lepodisiran would reach the market over the following two to three years.

In parallel, watch for Phase 3 initiation of muvalaplin, which could dramatically change the therapeutic landscape if oral dosing proves viable. Watch also for guideline updates from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology in the months following HORIZON. And watch for health system adoption of universal one time Lp(a) screening, which the availability of treatment will almost certainly accelerate.

One under discussed policy question is pricing. RNA therapeutics are expensive to develop and tend to launch at premium prices. PCSK9 inhibitors faced significant insurance coverage barriers for years after approval. How the Lp(a) therapies are priced, and how aggressively payers fight to limit access, will shape the real world impact of even the most dramatic trial results. The fact that Lp(a) therapy targets a clearly defined, genetically identifiable patient population may help rather than hurt those access conversations, since the cost effectiveness case is strongest when the highest risk population can be cleanly identified.

What This Means For You

If you have never had your Lp(a) level measured, now is the time to request it. A one time blood draw, often added to an existing lipid panel for a modest additional fee, will tell you for life whether you carry genetically elevated Lp(a). The information is especially important if you have a personal or family history of premature heart attack, stroke, or aortic valve disease.

A level above 50 mg/dL, or above 125 nmol/L in the molar units some laboratories report, is considered elevated. A level above 100 mg/dL is substantially elevated and places you in a high risk category regardless of your other numbers.

If your Lp(a) is high, the practical steps available today are aggressive management of every other modifiable cardiovascular risk factor. That means tight LDL control, ideally under 70 mg/dL, and under 55 mg/dL if you have any cardiovascular disease. Blood pressure under 120/80. Strict avoidance of tobacco. Regular aerobic and resistance exercise. And attention to sleep and metabolic health. Lowering the other risks does not change your Lp(a), but it reduces the absolute harm it can inflict.

For people with very high Lp(a) and existing cardiovascular disease, several of the RNA therapeutics are available through clinical trial participation right now. Clinicaltrials.gov lists active sites for HORIZON, OCEAN(a) Outcomes, and ACCLAIM-Lp(a) across every major U.S. metropolitan area. Participating not only provides potential early access to therapy but contributes data that will determine how the entire field moves forward.

Finally, if you are a parent or have adult children with a family history of premature cardiovascular disease, ask about testing them as well. Because Lp(a) is inherited, a single screening in one family member can identify risk across multiple generations. Children of parents with elevated Lp(a) have a 50 percent probability of inheriting the same risk, and that information changes everything about how their cardiovascular care should be structured over a lifetime.

For a condition that has silently driven cardiovascular death for decades, the most powerful thing you can do in 2026 is simply to know your number. The treatments are coming, and when they arrive, the people who will benefit most are those who already know they need them.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.